Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift.

World J Gastrointest Oncol · 2025 · PMC12179869 · PMID 40547153

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

a positive trendP = 0.06so close (0.05 < p ≤ 0.1)

In the overall population, OS was significantly improved in the toripalimab group, with 17 months in the experimental arm vs 11 months in the placebo group (HR = 0.58, 95%CI: 0.43-0.78; P = 0.0004), maintaining a positive trend in PD-L1 CPS ≥ 10 subgroup, though without reaching statistical significance (17.0 months vs 10.9 months, HR = 0.64, 95%CI: 0.40-1.03; P = 0.06)[ 26 ].

also in 4,297 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.